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FXI (factor XI) is an enzyme that is involved in thrombus propagation and stabilization. An observational study has 
suggested that individuals with FXI deficiency have reduced 
incidence of ischemic stroke (IS).1 Furthermore, reduction of 
FXI levels was effective for preventing postoperative venous 
thromboembolism in patients undergoing total knee arthro-
plasty, without any apparent increase in bleeding complica-
tions as compared with standard care.2
The Mendelian randomization (MR) technique uses ran-
domly allocated genetic variants that are related to an expo-
sure as instruments to investigate the effect of varying that 
exposure.3 To avoid bias, the genetic variants selected as 
instruments should only affect the outcome through the expo-
sure and not by some pleiotropic pathway. To this end, genetic 
variants related to FXI levels that are located at the F11 gene 
make viable instruments for use in MR.
We perform MR analyses using such instruments for FXI 
levels to investigate the effect of genetically determined FXI 
levels on risk of IS, IS etiological subtypes, and myocardial 
infarction (MI). To explore whether higher, genetically deter-
mined FXI levels cause increased risk of bleeding, we also 
examined associations with intracerebral hemorrhage (ICH).
Methods
The data used in this study are available from the corresponding au-
thor on reasonable request. Instruments and genetic association esti-
mates for FXI were obtained from a genome-wide association study 
of natural logarithm-transformed FXI levels in 16 169 European indi-
viduals.4 Instruments for the main analysis were selected as single-
nucleotide polymorphisms (SNPs) within 100 kb of the F11 gene 
(ie, chromosome 4 position 187,087,099-187,310,835 on GRCh37/
hg19) that had genome-wide significant associations with FXI lev-
els and were in low linkage disequilibrium with r2<0.001.4 Details 
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of studies used to obtain genetic association estimates for IS, IS sub-
types, MI, and ICH are provided in Methods in the online-only Data 
Supplement. All studies had obtained ethical approval.
Individual MR estimates for each SNP were calculated using 
the ratio method, with SEs derived with the Delta method.5 Overall 
MR estimates were obtained by pooling the MR results of individual 
SNPs using fixed-effects inverse-variance (IVW) meta-analysis.5 As 
a sensitivity analysis, we also performed an unweighted allele score 
that pooled the SNP-outcome estimates for the main FXI instruments 
using fixed-effects IVW meta-analysis. Such an approach does not 
consider the magnitude of effect for each SNP on FXI levels.
As a further sensitivity analysis using more SNPs, we also re-
peated the IVW MR using relaxed criteria for instrument selection. 
For this, we selected SNPs across the genome associated with nat-
ural logarithm-transformed FXI levels at P<5×10−6 and in low link-
age disequilibrium with r2<0.01. Using these instruments, we also 
performed the MR-Egger sensitivity analysis, which is more robust 
to the inclusion of pleiotropic instruments and offers a test for the 
presence of directional pleiotropy.6 A threshold of P<0.007 was used 
to determine statistical significance for all analyses, after applying a 
Bonferroni multiple testing correction for the 7 outcomes.
Results
The rs4253417 and rs62350309 SNPs were identified as 
instruments for FXI levels in the main analyses (Table I in 
the online-only Data Supplement). Individual MR estimates 
for each SNP and the overall IVW MR estimates are given 
in Figure 1 for IS, MI, and ICH and in Figure 2 for the IS 
subtypes. The 95% CIs overlapped for the 2 SNPs throughout.
The IVW MR analysis supported a causal effect of higher, 
genetically determined FXI levels on risk of any IS (odds ratio 
Figure 1. Forest plot of the individual single-
nucleotide polymorphism (SNP) and pooled 
Mendelian randomization (MR) estimates for 
the causal effect of FXI (factor XI) levels on risk 
of ischemic stroke, myocardial infarction, and 
intracerebral hemorrhage in the main analysis. 
IVW indicates inverse variance; and OR, odds 
ratio.
Figure 2. Forest plot of the individual single-
nucleotide polymorphism (SNP) and pooled 
Mendelian randomization (MR) estimates for the 
causal effect of FXI (factor XI) levels on risk of 
ischemic stroke etiological subtypes in the main 
analysis. IVW indicates inverse variance; and 
OR, odds ratio.
Gill et al  Factor XI and Stroke  2763
[OR] per 1-unit increase in natural logarithm-transformed FXI 
levels, 2.54; 95% CI, 1.68–3.84; P=1×10−5) but not MI (OR, 
1.01; 95% CI, 0.76–1.34; P=0.94) or ICH (OR, 1.81; 95% 
CI, 0.44–7.38; P=0.41; Figure 1). Examining IS subtypes, the 
results supported a causal effect of higher, genetically deter-
mined FXI levels on risk of cardioembolism (CE) (OR, 4.23; 
95% CI, 1.94–9.19; P=3×10−4) and IS of undetermined cause 
(OR, 3.44; 95% CI, 1.79–6.60; P=2×10−4) but not risk of large 
artery atherosclerosis (OR, 2.73; 95% CI, 1.15–6.45; P=0.02) 
or small artery occlusion (OR, 1.19; 95% CI, 0.50–2.82; 
P=0.69; Figure 2). Results of the unweighted allele score sup-
ported the main IVW MR findings, with concordant directions 
of effect and IS, P=4×10−4; MI, P=0.73; ICH, P=0.69; CE, 
P=0.003; large artery atherosclerosis, P=0.14; small artery 
occlusion, P=0.32; and IS of undetermined cause, P=0.001.
Using the more relaxed criteria for instrument selection, 
we identified 26 SNPs as instruments, with results for only 
15 of these available for ICH (Table II in the online-only Data 
Supplement). IVW MR and MR-Egger using these SNPs sup-
ported the findings of the main analysis for any IS and CE 
(Table III in the online-only Data Supplement). However, sta-
tistical significance (P<0.007) was not achieved for any of the 
other outcomes considered (Table III in the online-only Data 
Supplement) and in particular, IS of undetermined cause (IVW 
MR: OR, 1.56; 95% CI, 1.11–2.19; P=0.01; MR-Egger: OR, 
1.61; 95% CI, 0.89–2.92; P=0.12). There was no MR-Egger 
evidence for the presence of directional pleiotropy in any 
of the analyses (IS, P=0.75; MI, P=0.24; ICH, P=0.31; CE, 
P=0.07; large artery atherosclerosis, P=0.86; small artery 
occlusion, P=0.10; and IS of undetermined cause, P=0.87).
Discussion
Our findings are consistent with the observational associa-
tion of individuals with FXI deficiency having a lower risk of 
IS, but not MI,1 and also highlight FXI as a possible target to 
prevent IS. It is interesting to note the MR association of ge-
netically determined FXI levels with IS but not MI, despite 
existing novel oral anticoagulants proving efficacious for pre-
venting MI. The discrepancy may relate to differences in the 
action of FXI at various anatomic sites and vascular beds.1 In 
terms of the adverse effects associated with FXI level lowering, 
reduction using a second-generation antisense oligonucleotide 
to prevent postoperative venous thromboembolism was not as-
sociated with excessive bleeding as compared with standard 
care2 and similarly, we did not find evidence of a causal effect 
of genetically determined FXI levels on risk of ICH.
The major strength of our MR study is that it has allowed 
investigation of the causal effect of genetically determined 
FXI levels on risk of IS, IS etiological subtypes, MI, and ICH. 
The main IVW MR analysis maximizes statistical power but 
is prone to bias from the inclusion of pleiotropic instruments. 
In contrast, although the use of more relaxed instrument se-
lection criteria in sensitivity analyses possibly introduced bias 
through introduction of weak or invalid instruments, it allowed 
for MR-Egger sensitivity analysis (Table III in the online-only 
Data Supplement), which is more robust to inclusion of plei-
otropic instruments under the assumption that instrument 
strength is independent of any pleiotropic effect.6 In terms of 
weaknesses of our study, the negative findings may be related 
to lack of sufficient statistical power to detect an effect. In addi-
tion, we did not investigate bleeding phenotypes other than 
ICH. Furthermore, our MR analysis assumes a linear effect 
of natural logarithm-transformed FXI levels and reflects the 
lifetime cumulative consequence of higher, genetically deter-
mined FXI levels. Although the unweighted allele score, which 
does not consider the magnitude of effect that the instruments 
had on FXI levels, supported the main analysis, MR results 
should not be extrapolated to estimate the quantitative effect of 
clinical intervention. Indeed, this MR study does not provide 
data on the effect of clinically altering FXI levels.
Summary
Our MR study supports FXI as a possible target for reducing 
the risk of the CE subtype of IS. Importantly, it suggests a 
differential effect of genetically determined FXI on the risk of 
different IS subtypes, which may help future clinical studies 
target appropriate populations.
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